Cargando…

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ

This paper considers methods for estimating the association between progression‐free and overall survival in oncology trials. Copula‐based, nonparametric, and illness‐death model–based methods are reviewed. In addition, the approach based on an underlying illness‐death model is generalized to allow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weber, Enya M., Titman, Andrew C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585767/ https://www.ncbi.nlm.nih.gov/pubmed/30311243 http://dx.doi.org/10.1002/sim.8001

Ejemplares similares

Practical guide to using Kendall’s τ in the context of forecasting critical transitions
por: Chen, Shiyang, et al.
Publicado: (2022)

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
por: Hess, Lisa M, et al.
Publicado: (2019)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Dr. Kendall
Publicado: (1901)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Herbert W. Kendall
Publicado: (1907)

Kendall's advanced theory of statistics
por: Kendall, Maurice G. (Maurice George), 1907-1983
Publicado: (1987)

Kendall's advanced theory of statistics
por: Stuart, Alan, et al.
Publicado: (1994)

Account of the Epidemic Cholera of Kendal
por: Proudfoot, Thomas
Publicado: (1833)

Dr. James V. Kendall
Publicado: (1901)

Topographical Pathology of Kendal and Its Neighbourhood
por: Proudfoot, Thomas
Publicado: (1822)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
por: Okabe, Ayano, et al.
Publicado: (2023)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
por: Solomon, B.J., et al.
Publicado: (2022)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
por: Ton, Thanh G.N., et al.
Publicado: (2022)

Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study
por: Tang, Yiyun, et al.
Publicado: (2014)

Tau leptons and the decay H → τ τ at CMS
por: Nehrkorn, Alexander
Publicado: (2016)

(τ(1),τ(2))δ-semicontinuous multifunctions
por: Boonpok, Chawalit
Publicado: (2020)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Glioblastoma: A Retrospective Analysis of the Role of the Maximal Surgical Resection on Overall Survival and Progression Free Survival
por: Polonara, Gabriele, et al.
Publicado: (2023)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Low plateletcrit is associated with reduced progression: Free and overall survival in chronic lymphocytic leukemia
por: Ozbalci, Demircan, et al.
Publicado: (2023)

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
por: Aboshi, Masayuki, et al.
Publicado: (2014)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

An O(n) method of calculating Kendall correlations of spike trains
por: Redman, William
Publicado: (2019)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site
por: Grajales-Álvarez, Rocío, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bkaajkgqf6cf3n5sf9mk9gbajg